Document is current

Article History

Received: 21 September 2024

Accepted: 5 November 2024

First Online: 15 November 2024

Declarations

:

: Oluwadamilola Onasanya is an employee of Carelon Research, an organization that conducts contract research for life sciences companies, payers, and government agencies. Susan dosReis receives funding from GSK for work unrelated to the content of the manuscript. She also consults for Alexion Pharmaceuticals. Wendy Camelo Castillo was supported in part by a research grant from Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp, unrelated to this work. Dr. Onukwugha receives funding from Organon for work unrelated to the content of this manuscript.

: The University of Maryland Baltimore Institutional Review Board deemed this study exempt.

: The content expressed in this paper is solely the responsibility of the authors and does not necessarily represent the official view of the National Cancer Institute. The statements, findings, conclusions, views, and opinions contained and expressed in this manuscript are based in part on data obtained under license from IQVIA. The statements, findings, conclusions, views, and opinions contained and expressed herein are not necessarily those of IQVIA or any of its affiliated or subsidiary entities. Source: IQVIA PharMetrics® Plus for Academics, January 2006–December 2022. All Rights Reserved.